

## Index to volume 52

### Author index

#### A

- Aaes-Jørgensen T (see Sindrup et al). 1992;52:547-52  
 Abernethy DR (see Andrawis et al). 1992;52:583-9  
 Abou-Donia M (see Schmith et al). 1992;52:528-36  
 Abraham PA, Halstenson CE, Macres MM, Opsahl JA, Rank BH, Schwenk MH, Lasky LC, Cohen A, Lasseter KC, Smith DL, Larkin S, Whalen JJ. Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies. 1992;52:205-13  
 Adedoyin A (see Zhou et al). 1992;52:120-4  
 Ader R (see Suchman and Ader). 1992;52:372-7  
 Affrime MB (see Billah et al). 1992;52:151-9  
 Akselrod S (see Alcalay et al). 1992;52:518-27  
 Alcalay M, Izraeli S, Wallach-Kapon R, Tochner Z, Benjamini Y, Akselrod S. Paradoxical pharmacodynamic effect of atropine on parasympathetic control: a study by spectral analysis of heart rate fluctuations. 1992;52:518-27  
 Altieri I (see Rosa et al). 1992;52:324-9  
 Alton C (see Lindholm et al). 1992;52:359-71  
 Andrawis NS, Gilligan J, Abernethy DR. Endothelin-I-mediated vasoconstriction: specific blockade by verapamil. 1992;52:583-9  
 Andros EA (see Nies et al). 1992;52:605-8  
 Annesley TM (see Turgeon et al). 1992;52:471-8  
 Antal EJ (see Friedman et al). 1992;52:139-50  
 Anttila M (see Scheinin et al). 1992;52:537-46  
 Aoki FY (see Sitar et al). 1992;52:297-306  
 Avram MJ (see Henthorn et al). 1992;52:190-6  
 Ayers GD (see Relling et al). 1992;52:643-58

#### B

- Baettig D (see Breyer-Pfaff et al). 1992;52:350-8  
 Bauer LA, Schumock G, Horn J, Opheim K. Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. 1992;52:6-10  
 Baumann P (see Breyer-Pfaff et al). 1992;52:350-8  
 Belz GG, Bliessath H, Essig J, Neumann N, Zech K, Wurst W. Differential effects of two dihydropyridine calcium antagonists in humans. 1992;52:68-79  
 — (see de Mey et al). 1992;52:609-19  
 — (see Schmitt et al). 1992;52:314-23  
 Benet LZ (see Haefeli et al). 1992;52:590-6  
 — (see Hebert et al). 1992;52:453-7  
 Benjamini Y (see Alcalay et al). 1992;52:518-27  
 Benowitz NL, Jacob P III, Olsson P, Johansson CJ. Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption. 1992;52:223-30  
 Beretta-Piccoli C (see Donati et al). 1992;52:50-9

- Bergmann JF, Chassany O, Simoneau G, Lemaire M, Segrestaa JM, Caulin C. Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses. 1992;52:413-6  
 Bianchini JR (see Narang et al). 1992;52:335-41  
 Billah MM, Gilchrist HG, Eckel SP, Granzow CA, Lawton PJ, Radwanski E, Brannan MD, Affrime MB, Christopher JD, Richards W, Siegel MI. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans. 1992;52:151-9  
 Bindley PF (see Tice et al). 1992;52:496-503  
 Bixler EO (see Vgontzas et al). 1992;52:110-1 (Letter reply)  
 Bjerre U (see Sindrup et al). 1992;52:547-52  
 Black C, May G, Csuka ME, Lupoli S, Wilkinson GR, Branch RA. Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease. 1992;52:659-67  
 Blaschke TF (see Haefeli et al). 1992;52:590-6  
 Bliessath H (see Belz et al). 1992;52:68-79  
 Blychert E, Edgar B, Elmfeldt D, Hedner T. Plasma concentration-effect relationships for felodipine: a meta analysis. 1992;52:80-9  
 Borgström L (see Bredberg et al). 1992;52:239-48  
 Botteron GW (see Hurwitz et al). 1992;52:108-9 (Letter reply)  
 Brackett CC. Vancomycin levels and acute renal failure. 1992;52:570 (Letter)  
 Branch RA (see Black et al). 1992;52:659-67  
 Brannan MD (see Billah et al). 1992;52:151-9  
 Braudo M (see Matsui et al). 1992;52:102-3  
 Bredberg U, Karlsson MO, Borgström L. A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. 1992;52:239-48  
 Breimer DD (see van Steveninck et al). 1992;52:402-8  
 Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perey M, Baettig D, Baumann P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. 1992;52:350-8  
 Brockmüller J (see Rost et al). 1992;52:170-80  
 Brooks C (see Rodda et al). 1992;52:104-5 (Letter)  
 Brøsen K (see Sindrup et al). 1992;52:547-52  
 Brösicke H (see Rost et al). 1992;52:170-80  
 Bühler FR (see Donati et al). 1992;52:50-9  
 Bullingham RES (see Maunukela et al). 1992;52:436-43  
 — (see Whitehead et al). 1992;52:197-204  
 Buntinx A (see Depré et al). 1992;52:409-12  
 Busch M (see Sullivan et al). 1992;52:635-42  
 Butzer R (see de Mey et al). 1992;52:609-19

#### C

- Cameron DW (see Sahai et al). 1992;52:464-70  
 Cantilena LR Jr (see Honig et al). 1992;52:231-8

July, pp. 1-114; August, pp. 115-222; September, pp. 223-334; October, pp. 335-448; November, pp. 449-576; December, pp. 577-690.

- Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Das K. The feasibility of studying drug-induced acute hepatitis with use of Medicaid data. 1992;52:214-9
- Caulin C (see Bergmann et al). 1992;52:413-6
- Charlton MD (see Friedman et al). 1992;52:139-50
- Chassany O (see Bergmann et al). 1992;52:413-6
- Chiba K (see Sohn et al). 1992;52:160-9
- Chouinard ML, Martin LL, Coffman T, Hamilton BH, Linberg LF, Pamidi A, Simke JP, Rakshit A. Pharmacokinetics and biochemical efficacy of pimaragrel, a thromboxane synthase inhibitor, in renal allograft recipients. 1992;52:597-604
- Christopher JD (see Billah et al). 1992;52:151-9
- Cloud ML, Enas N, Offen WW, Nizatidine Benign Gastric Ulcer Disease Study Group. Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. 1992;52:307-13
- Coffman T (see Chouinard et al). 1992;52:597-604
- Cohen A (see Abraham et al). 1992;52:205-13
- Cohen AF (see van Steveninck et al). 1992;52:402-8
- Cone EJ (see Huestis et al). 1992;52:31-41
- Conner DP (see Honig et al). 1992;52:231-8
- Cooper MR, Lieberman R, La Rocca RV, Gernit PR, Weinberger MS, Headlee DJ, Kohler DR, Goldspiel BR, Peck CC, Myers CE. Adaptive control with feedback strategies for suramin dosing. 1992;52:11-23
- Cotureau MM (see Greenblatt et al). 1992;52:479-86
- Cournot A (see van Harten et al). 1992;52:427-35
- Cox S (see Kelley et al). 1992;52:181-9
- Cramond T (see Leow et al). 1992;52:487-95
- Csuka ME (see Black et al). 1992;52:659-67
- Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, Kreek MJ. Treatment of opioid-induced constipation with oral naloxone: a pilot study. 1992;52:90-5
- D**
- Darmansjah I, Muchtar A. Dose-response variation among different populations. 1992;52:449-52 (Commentary)
- Das K (see Carson et al). 1992;52:214-9
- Dejgaard A (see Sindrup et al). 1992;52:547-52
- de Mey C, Belz GG, Nixdorf U, Butzer R, Schroeter V, Meyer J, Erbel R. Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers. 1992;52:609-19
- Depré M, Meeter C, Van Hecken A, Laskin OL, Buntinx A, De Schepper PJ. Pharmacodynamics and tolerability of L-654,066, a steroid 5 $\alpha$ -reductase inhibitor in men. 1992;52:409-12
- Dershwitz M, Rosow CE, Di Biase PM, Joslyn AF, Sanderson PE. Ondansetron is effective in decreasing postoperative nausea and vomiting. 1992;52:96-101
- De Schepper PJ (see Depré et al). 1992;52:409-12
- D'Estanque J (see Provost et al). 1992;52:384-93
- Di Biase PM (see Dershwitz et al). 1992;52:96-101
- Donati L, Bühler FR, Beretta-Piccoli C, Kusch F, Heinen G. Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. 1992;52:50-9
- Drees B (see Lameire et al). 1992;52:24-30
- Duff A (see Carson et al). 1992;52:214-9
- E**
- Ebihara K (see Hashiguchi and Ebihara). 1992;52:274-6
- Eckardt MJ (see George et al). 1992;52:553-60
- Eckel SP (see Billah et al). 1992;52:151-9
- Edgar B (see Blychert et al). 1992;52:80-9
- Edge JH (see Kelley et al). 1992;52:181-9
- Ego D (see Provost et al). 1992;52:384-93
- Elmfeldt D (see Blychert et al). 1992;52:80-9
- Enas N (see Cloud et al). 1992;52:307-13
- Erbel R (see de Mey et al). 1992;52:609-19
- Essig J (see Belz et al). 1992;52:68-79
- Evans WE (see Relling et al). 1992;52:643-58
- Ezra D (see Lubetsky et al). 1992;52:42-9
- F**
- Feifel U (see Schmitt et al). 1992;52:314-23
- Fiedler-Kelly J (see Schmitt et al). 1992;52:528-36
- Fishman K (see Watkins et al). 1992;52:265-73
- Flouvat B (see Lefebvre et al). 1992;52:458-63
- Foley K (see Culpepper-Morgan et al). 1992;52:90-5
- Fonte C (see Perkins et al). 1992;52:627-34
- Francom SF (see Friedman et al). 1992;52:139-50
- Friedman H, Greenblatt DJ, Peters GR, Metzler CM, Charlton MD, Harmatz JS, Antal EJ, Sanborn EC, Francom SF. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. 1992;52:139-50
- Fuhr U (see Rost et al). 1992;52:107-8 (Letter)
- Fukuda T (see Sato et al). 1992;52:249-51
- Funck-Brentano C (see Le Coz et al). 1992;52:417-26
- (see Provost et al). 1992;52:384-93
- G**
- Gallicano K (see Sahai et al). 1992;52:464-70
- Gancher ST, Nutt JG, Woodward WR. Time course of tolerance to apomorphine in parkinsonism. 1992;52:464-70
- Garber G (see Sahai et al). 1992;52:464-70
- George DT, Lindquist T, Rawlings RR, Eckardt MJ, Moss H, Mathis C, Martin PR, Linnoila M. Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa. 1992;52:553-60
- Gerber JG (see Nies et al). 1992;52:605-8
- Gerdin E (see Rane et al). 1992;52:257-64
- Gernit PR (see Cooper et al). 1992;52:11-23
- Gilchrist HG (see Billah et al). 1992;52:151-9
- Gilligan J (see Andrawis et al). 1992;52:583-9
- Goettler JE (see Perkins et al). 1992;52:627-34
- Goldspiel BR (see Cooper et al). 1992;52:11-23
- Gram LF (see Sindrup et al). 1992;52:547-52
- Granzow CA (see Billah et al). 1992;52:151-9
- Grasela TH Jr (see Schmitt et al). 1992;52:528-36
- Gratz SS (see Simpson and Gratz). 1992;52:286-91
- Greenblatt DJ, Preskorn SH, Cotureau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. 1992;52:479-86
- (see Friedman et al). 1992;52:139-50
- Grobe JE (see Perkins et al). 1992;52:627-34
- Gumbleton M (see Haefeli et al). 1992;52:590-6
- Gupta A (see Carson et al). 1992;52:214-9
- Guzeljan PS (see Watkins et al). 1992;52:265-73
- H**
- Haefeli WE, Gumbleton M, Benet LZ, Hoffman BB, Blaschke TF. Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. 1992;52:590-6
- Halabi A (see Schmitt et al). 1992;52:314-23
- Halkin H (see Lubetsky et al). 1992;52:42-9
- Halstenson CE (see Abraham et al). 1992;52:205-13
- Hamilton BH (see Chouinard et al). 1992;52:597-604
- Hamilton T (see Watkins et al). 1992;52:265-73
- Harmatz JS (see Friedman et al). 1992;52:139-50
- Harmatz JS (see Greenblatt et al). 1992;52:479-86
- Harron DWG (see McKaigue and Harron). 1992;52:511-7

- Hashiguchi M, Ebihara K. Acetylation polymorphism of caffeine in a Japanese population. 1992;52:274-6
- Hawley-Foss N (see Sahai et al). 1992;52:464-70
- Headlee DJ (see Cooper et al). 1992;52:11-23
- Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. 1992;52:453-7
- Hedner J (see Hirsch et al). 1992;52:394-401
- Hedner T (see Blychert et al). 1992;52:80-9
- (see Hirsch et al). 1992;52:394-401
- Heinen G (see Donati et al). 1992;52:50-9
- Helge H (see Rost et al). 1992;52:170-80
- Henningfield JE (see Huestis et al). 1992;52:31-41
- Henthorn TK, Krejcie TC, Avram MJ. The relationship between alfentanil distribution kinetics and cardiac output. 1992;52:190-6
- Hermann C (see Matsui et al). 1992;52:102-3
- Hirsch JM, Hedner J, Wemstedt L, Lundberg JM, Hedner T. Hemodynamic effects of the use of oral snuff. 1992;52:394-401
- Hoffman BB (see Haefeli et al). 1992;52:590-6
- Holicky BJ (see Huestis et al). 1992;52:31-41
- Holland RL (see van Harten et al). 1992;52:427-35
- Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. 1992;52:231-8
- Horn J (see Bauer et al). 1992;52:6-10
- Horst WD (see Greenblatt et al). 1992;52:479-86
- Houde RW (see Culppepper-Morgan et al). 1992;52:90-5
- Hsia HC (see Lin et al). 1992;52:134-8
- Huang L (see Sahai et al). 1992;52:464-70
- Hubbard JW (see Srinivas et al). 1992;52:561-8
- Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. 1992;52:31-41
- Huffman CS (see Schmith et al). 1992;52:528-36
- Hughes EM (see Hurwitz et al). 1992;52:108-9 (Letter reply)
- Hui KK. Pharmacokinetics of fosinopril. 1992;52:569 (Letter reply)
- Hunter DJS, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. 1992;52:60-7
- Hurwitz A, Vacek JL, Botteron GW, Sztren MI, Hughes EM, Jayaraj A. Theophylline metabolism affected by mexiletine. 1992;52:108-9 (Letter reply)
- Hutabarat RH (see Unadkat et al). 1992;52:106-7 (Letter reply)

# I

- Inturrisi CE (see Culppepper-Morgan et al). 1992;52:90-5
- Ishizaki T (see Sohn et al). 1992;52:160-9
- Ito S (see Matsui et al). 1992;52:102-3
- Iversen HK. N-Acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses. 1992;52:125-33
- Izraeli S (see Alcalay et al). 1992;52:518-27

# J

- Jacob P III (see Benowitz et al). 1992;52:223-30
- Jaillon P (see Le Coz et al). 1992;52:417-26
- (see Provost et al). 1992;52:384-93
- Jang JJ (see Sohn et al). 1992;52:160-9
- Jasinski DR (see Sullivan et al). 1992;52:635-42
- Jayaraj A (see Hurwitz et al). 1992;52:108-9 (Letter reply)
- Johansson CJ (see Benowitz et al). 1992;52:223-30
- Jonzier-Perey M (see Breyer-Pfaff et al). 1992;52:350-8
- Joslyn AF (see Dershwitz et al). 1992;52:96-101
- Jungbluth GL (see Tice et al). 1992;52:496-503

# K

- Kahan BD (see Lindholm et al). 1992;52:359-71
- Kales A (see Vgontzas et al). 1992;52:110-1 (Letter reply)
- Kallio A (see Scheinin et al). 1992;52:537-46
- Karhapää P, Uusitupa M, Voutilainen E, Laakso M. Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia. 1992;52:620-6
- Karhuvaara S (see Scheinin et al). 1992;52:537-46
- Karlsson MO (see Bredberg et al). 1992;52:239-48
- Karolac-Tamisier S (see Lefebvre et al). 1992;52:458-63
- Kelley MT, Walson PD, Edge JH, Cox S, Mortensen ME. Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. 1992;52:181-9
- Kibleur Y (see Le Coz et al). 1992;52:417-26
- Kirch W (see Schmitt et al). 1992;52:314-23
- Kleinbloesem CH (see Schmitt et al). 1992;52:314-23
- Kohler DR (see Cooper et al). 1992;52:11-23
- Koivisto M (see Pokela et al). 1992;52:342-9
- Kokki H (see Maunukela et al). 1992;52:436-43
- Kolars JC (see Watkins et al). 1992;52:265-73
- Koren G (see Matsui et al). 1992;52:102-3
- Kreek MJ (see Culppepper-Morgan et al). 1992;52:90-5
- Krejcie TC (see Henthorn et al). 1992;52:190-6
- Kroon R (see van Steveninck et al). 1992;52:402-8
- Kusaka M (see Sohn et al). 1992;52:160-9
- Kusch F (see Donati et al). 1992;52:50-9

# L

- Laakso M (see Karhapää et al). 1992;52:620-6
- Lameire N, Malerczyk V, Drees B, Lehr K, Rosenkranz B. Single-dose pharmacokinetics of cefpirome in patients with renal impairment. 1992;52:24-30
- Larkin S (see Abraham et al). 1992;52:205-13
- La Rocca RV (see Cooper et al). 1992;52:11-23
- Laskin OL (see Depré et al). 1992;52:409-12
- Lasky LC (see Abraham et al). 1992;52:205-13
- Lasky T (see Stolley and Lasky). 1992;52:1-3 (Commentary)
- Lasseter KC (see Abraham et al). 1992;52:205-13
- Lawton PJ (see Billah et al). 1992;52:151-9
- Lebsack ME, Nix D, Ryerson B, Toothaker RD, Welage L, Norman AM, Schentag JJ, Sedman AJ. Effect of gastric acidity on enoxacin absorption. 1992;52:252-6
- Le Coz F, Funck-Brentano C, Poirier JM, Kibleur Y, Mazoit FX, Jaillon P. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. 1992;52:417-26
- Lee FY (see Lin et al). 1992;52:134-8
- Lee SD (see Lin et al). 1992;52:134-8
- Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, Van Ganse E. Influence of lansoprazole treatment on diazepam plasma concentrations. 1992;52:458-63
- Lehr K (see Lameire et al). 1992;52:24-30
- Leichtman AB (see Turgeon et al). 1992;52:471-8
- Leier CV (see Tice et al). 1992;52:496-503
- Lemaire M (see Bergmann et al). 1992;52:413-6
- Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. 1992;52:487-95
- Levy G. Publication bias: its implications for clinical pharmacology. 1992;52:115-9 (Commentary)
- Lewis RC (see Narang et al). 1992;52:335-41
- Lieberman R (see Cooper et al). 1992;52:11-23
- Lin HC, Tsai YT, Lee SD, Lee FY, Hsia HC, Meng HC, Wang SS, Lo KJ. Octreotide decreased liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis. 1992;52:134-8
- Lin JS (see Relling et al). 1992;52:643-58

- Linberg LF (see Chouinard et al). 1992;52:597-604  
 Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. 1992;52:359-71  
 Lindquist T (see George et al). 1992;52:553-60  
 Linnoila M (see George et al). 1992;52:553-60  
 Lloyd J (see Whitehead et al). 1992;52:197-204  
 Lo KJ (see Lin et al). 1992;52:134-8  
 Lown KS (see Watkins et al). 1992;52:265-73  
 Lubetsky A, Seligsohn U, Ezra D, Halkin H. The effect of the plasma levels of proteins C and S on the prediction of warfarin maintenance dose requirements. 1992;52:42-9  
 Lundberg JM (see Hirsch et al). 1992;52:394-401  
 Lupoli S (see Black et al). 1992;52:659-67

## M

- Macias WL (see Mueller et al). 1992;52:570-1 (Letter reply)  
 MacKichan JJ (see Tice et al). 1992;52:496-503  
 Macres MM (see Abraham et al). 1992;52:205-13  
 Malerczyk V (see Lameire et al). 1992;52:24-30  
 Manfredi RL (see Vgontzas et al). 1992;52:110-1 (Letter reply)  
 Marsh F (see Culpepper-Morgan et al). 1992;52:90-5  
 Martin LL (see Chouinard et al). 1992;52:597-604  
 Martin PR (see George et al). 1992;52:553-60  
 Mathis C (see George et al). 1992;52:553-60  
 Matsui D, Hermann C, Braudo M, Ito S, Olivieri N, Koren G. Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance. 1992;52:102-3  
 Maunukela EL, Kokki H, Bullingham RES. Comparison of intravenous ketorolac with morphine for postoperative pain in children. 1992;52:436-43  
 May G (see Black et al). 1992;52:659-67  
 Mazoit FX (see Le Coz et al). 1992;52:417-26  
 McGillveray I (see Sahai et al). 1992;52:464-70  
 McKaigue JP, Harron DWG. The effects of rilmenidine on tests of autonomic function in humans. 1992;52:511-7  
 Meeter C (see Depré et al). 1992;52:409-12  
 Meng HC (see Lin et al). 1992;52:134-8  
 Metzler CM (see Friedman et al). 1992;52:139-50  
 Meyer J (see de Mey et al). 1992;52:609-19  
 Midha KK (see Srinivas et al). 1992;52:561-8  
 Mindel JS. Failure of controlled clinical trial data to reach the literature. 1992;52:4-5 (Commentary)  
 Modiri AR (see Rane et al). 1992;52:257-64  
 Moerman E (see Lefebvre et al). 1992;52:458-63  
 Mohrland JS (see Tice et al). 1992;52:496-503  
 Monney C (see Breyer-Pfaff et al). 1992;52:350-8  
 Moore UJ, Seymour RA, Rawlins MD. The efficacy of locally applied aspirin and acetaminophen in postoperative pain after third molar surgery. 1992;52:292-6  
 Mortensen ME (see Kelley et al). 1992;52:181-9  
 Moss H (see George et al). 1992;52:553-60  
 Muchtar A (see Damansjah and Muchtar). 1992;52:449-52 (Commentary)  
 Mueller BA, Scarim SK, Macias WL. Vancomycin levels and acute renal failure. 1992;52:570-1 (Letter reply)  
 Myers CE (see Cooper et al). 1992;52:11-23

## N

- Naito H (see Sato et al). 1992;52:249-51  
 Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability and food effect. 1992;52:335-41  
 Neumann N (see Belz et al). 1992;52:68-79  
 Nies AS, Andros EA, Gerber JG. Platelet  $\alpha_2$ -adrenergic receptor responsiveness is increased in elderly men but not in elderly women. 1992;52:605-8

- Nil K (see Breyer-Pfaff et al). 1992;52:350-8  
 Nix D (see Lebsack et al). 1992;52:252-6  
 Nixdorf U (see de Mey et al). 1992;52:609-19  
 Nizatidine Benign Gastric Ulcer Disease Study Group (see Cloud et al). 1992;52:307-13  
 Norman AM (see Lebsack et al). 1992;52:252-6  
 Normolle DP (see Turgeon et al). 1992;52:471-8  
 Nusser E (see Breyer-Pfaff et al). 1992;52:350-8  
 Nutt JG (see Ganchar et al). 1992;52:504-10

## O

- Offen WW (see Cloud et al). 1992;52:307-13  
 Okubo N (see Sato et al). 1992;52:249-51  
 Olivieri N (see Matsui et al). 1992;52:102-3  
 Olkkola KT (see Pokela et al). 1992;52:342-9  
 — (see Scheinin et al). 1992;52:537-46  
 Olsson P (see Benowitz et al). 1992;52:223-30  
 Opheim K (see Bauer et al). 1992;52:6-10  
 Opsahl JA (see Abraham et al). 1992;52:205-13  
 O'Sullivan GM (see Whitehead et al). 1992;52:197-204  
 Ottaviani G (see Rosa et al). 1992;52:324-9

## P

- Pacifici R (see Rosa et al). 1992;52:324-9  
 Pakuts A (see Sahai et al). 1992;52:464-70  
 Palatini P, Racioppa A, Raule G, Zaninotto M, Penzo M, Pessina AC. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. 1992;52:378-83  
 Pamidi A (see Chouinard et al). 1992;52:597-604  
 Peck CC (see Cooper et al). 1992;52:11-23  
 Penzo M (see Palatini et al). 1992;52:378-83  
 Perkins KA, Grobe JE, Stiller RL, Fonte C, Goettler JE. Nasal spray nicotine replacement suppresses cigarette smoking desire and behavior. 1992;52:627-34  
 Pessina AC (see Palatini et al). 1992;52:378-83  
 Peters GR (see Friedman et al). 1992;52:139-50  
 Pfandl B (see Breyer-Pfaff et al). 1992;52:350-8  
 Pichini S (see Rosa et al). 1992;52:324-9  
 Pieters MSM (see van Steveninck et al). 1992;52:402-8  
 Poirier JM (see Le Coz et al). 1992;52:417-26  
 Pokela ML, Olkkola KT, Koivisto M, Ryhänen P. Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. 1992;52:342-9  
 Portenoy RK (see Culpepper-Morgan et al). 1992;52:90-5  
 Pozenel H (see Schmitt et al). 1992;52:314-23  
 Preskorn SH (see Greenblatt et al). 1992;52:479-86  
 Preston KL (see Sullivan et al). 1992;52:635-42  
 Provost JC, Funk-Brentano C, Rovei V, D'Estanque J, Ego D, Jaillon P. Pharmacokinetic and pharmacodynamic interaction between tolaxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. 1992;52:384-93  
 Prueksaritanont T (see Hebert et al). 1992;52:453-7

## Q

- Quinn D (see Srinivas et al). 1992;52:561-8

## R

- Racioppa A (see Palatini et al). 1992;52:378-83  
 Radwanski E (see Billah et al). 1992;52:151-9  
 Raghoebar M (see van Harten et al). 1992;52:427-35  
 Rakhit A (see Chouinard et al). 1992;52:597-604  
 Rane A, Modiri AR, Gerdin E. Ethylmorphine O-deethylation cosgregates with the debrisoquin genetic metabolic polymorphism. 1992;52:257-64

- Rank BH (see Abraham et al). 1992;52:205-13  
 Raule G (see Palatini et al). 1992;52:378-83  
 Rawlings RR (see George et al). 1992;52:553-60  
 Rawlins MD (see Moore et al). 1992;52:292-6  
 Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in *N*-acetyltransferase, xanthine oxidase, and CYP1A2 activities. 1992;52:643-58  
 Reynolds G (see Rodda et al). 1992;52:104-5 (Letter)  
 Richards W (see Billah et al). 1992;52:151-9  
 Roberts JP (see Hebert et al). 1992;52:453-7  
 Rodda BE, Brooks C, Reynolds G. Statistics and clinical trials. 1992;52:104-5 (Letter)  
 Roots I (see Rost et al). 1992;52:107-8 (Letter)  
 — (see Rost et al). 1992;52:170-80  
 Rosa M, Pacifici R, Altieri I, Pichini S, Ottaviani G, Zuccaro P. How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake. 1992;52:324-9  
 Rosenkranz B (see Lameire et al). 1992;52:24-30  
 Rosow CE (see Dershwitz et al). 1992;52:96-101  
 Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots I. Increase of cytochrome P4501A2 activity by omeprazole: evidence by the <sup>13</sup>C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of *S*-mephenytoin. 1992;52:170-80  
 —, Fuhr U, Roots I, Staib AH. Theophylline metabolism affected by mexiletine. 1992;52:107-8 (Letter)  
 Rovei V (see Provost et al). 1992;52:384-93  
 Ryerson B (see Lebsack et al). 1992;52:252-6  
 Ryhänen P (see Pokela et al). 1992;52:342-9

S

- Saenger P (see Watkins et al). 1992;52:265-73  
 Sahai J, Gallicano K, Garber G, Pakuts A, Hawley-Foss N, Huang L, McGilveray I, Cameron DW. Evaluation of the *in vivo* effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. 1992;52:464-70  
 Sampson AH (see Huestis et al). 1992;52:31-41  
 Sanborn EC (see Friedman et al). 1992;52:139-50  
 Sanderson PE (see Dershwitz et al). 1992;52:96-101  
 Sato S, Okubo N, Fukuda T, Takahashi H, Naito H. Arteriovenous differences of blood alcohol concentrations after celiac plexus block. 1992;52:249-51  
 Scarim SK (see Mueller et al). 1992;52:570-1 (Letter reply)  
 Scheffler M (see Rost et al). 1992;52:170-80  
 Scheinin H, Karhuvaara S, Olkkola KT, Kallio A, Anttila M, Vuorilehto L, Scheinin M. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. 1992;52:537-46  
 Scheinin M (see Scheinin et al). 1992;52:537-46  
 Schentag JJ (see Lebsack et al). 1992;52:252-6  
 Schmith VD, Fiedler-Kelly J, Abou-Donia M, Huffman CS, Grasele TH Jr. Population pharmacodynamics of doxacurium. 1992;52:528-36  
 Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woitiez AJJ, Welker HA, van Brummelen P. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. 1992;52:314-23  
 Schoemaker HC (see van Steveninck et al). 1992;52:402-8  
 Schroeter V (see de Mey et al). 1992;52:609-19  
 — (see Schmitt et al). 1992;52:314-23  
 Schulz P (see Hunter et al). 1992;52:60-7  
 Schumock G (see Bauer et al). 1992;52:6-10  
 Schwenk MH (see Abraham et al). 1992;52:205-13  
 Sedman AJ (see Lebsack et al). 1992;52:252-6  
 Segrestaa JM (see Bergmann et al). 1992;52:413-6  
 Seligsohn U (see Lubetsky et al). 1992;52:42-9  
 Seymour RA (see Moore et al). 1992;52:292-6

- Shahinfar S, Shaw WC. Pharmacokinetics of fosinopril. 1992;52:569 (Letter)  
 Shaw M (see Carson et al). 1992;52:214-9  
 Shaw WC (see Shahinfar and Shaw). 1992;52:569 (Letter)  
 Sheiner LB. Statistics and clinical trials. 1992;52:105-6 (Letter reply)  
 Shin JG (see Sohn et al). 1992;52:160-9  
 Shin SG (see Sohn et al). 1992;52:160-9  
 Siegel MI (see Billah et al). 1992;52:151-9  
 Simke JP (see Chouinard et al). 1992;52:597-604  
 Simoneau G (see Bergmann et al). 1992;52:413-6  
 Simpson GM, Gratz SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. 1992;52:286-91  
 Sindrup SH, Bjerre U, Dejgaard A, Brøsen K, Aaes-Jørgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. 1992;52:547-52  
 Sitar DS, Warren CP, Aoki FY. Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma. 1992;52:297-306  
 Smith AL (see Unadkat et al). 1992;52:106-7 (Letter reply)  
 Smith DE (see Turgeon et al). 1992;52:471-8  
 Smith DL (see Abraham et al). 1992;52:205-13  
 Smith MT (see Leow et al). 1992;52:487-95  
 Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, Chiba K. Incidence of *S*-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. 1992;52:160-9  
 Spielberg SP, Tobert JA. HMG-CoA reductase inhibitors and sleep. 1992;52:109-10 (Letter)  
 Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantioselective pharmacokinetics and pharmacodynamics of *dl*-threo-methylphenidate in children with attention deficit hyperactivity disorder. 1992;52:561-8  
 Staib AH (see Rost et al). 1992;52:107-8 (Letter)  
 Stevens LA (see van Harten et al). 1992;52:427-35  
 Stiller RL (see Perkins et al). 1992;52:627-34  
 Stolley PD, Lasky T. Shortcuts in drug evaluation. 1992;52:1-3 (Commentary)  
 Strom BL (see Carson et al). 1992;52:214-9  
 Suchman AL, Ader R. Classic conditioning and placebo effects in crossover studies. 1992;52:372-7  
 Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR. Psychoactivity and abuse potential of sumatriptan. 1992;52:635-42  
 Sztrem MI (see Hurwitz et al). 1992;52:108-9 (Letter reply)

T

- Takahashi H (see Sato et al). 1992;52:249-51  
 Testa MP (see Sullivan et al). 1992;52:635-42  
 Tice FD, Jungbluth GL, Bindley PF, MacKichan JJ, Mohrland JS, Wolf DL, Leier CV. Clinical pharmacology of nicorandil in patients with congestive heart failure. 1992;52:496-503  
 Tobert JA (see Spielberg and Tobert). 1992;52:109-10 (Letter)  
 Tochner Z (see Alcalay et al). 1992;52:518-27  
 Tonkin A, Wing L. Aging and susceptibility to drug-induced orthostatic hypotension. 1992;52:277-85  
 Toothaker RD (see Lebsack et al). 1992;52:252-6  
 Tsai YT (see Lin et al). 1992;52:134-8  
 Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. 1992;52:471-8  
 — (see Watkins et al). 1992;52:265-73  
 Tyson KL (see Vgontzas et al). 1992;52:110-1 (Letter reply)



## U

- Unadkat JD, Hutabarat RH, Smith AL. Drug clearance in patients with cystic fibrosis. 1992;52:106-7 (Letter reply)  
Uusitupa M (see Karhapää et al). 1992;52:620-6

## V

- Vacek JL (see Hurwitz et al). 1992;52:108-9 (Letter reply)  
van Brummelen P (see Schmitt et al). 1992;52:314-23  
Van Ganse E (see Lefebvre et al). 1992;52:458-63  
van Harten J, Stevens LA, Raghoobar M, Holland RL, Wesnes K, Cournot A. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. 1992;52:427-35  
Van Hecken A (see Depré et al). 1992;52:409-12  
van Steveninck AL, Verver S, Schoemaker HC, Pieters MSM, Kroon R, Breimer DD, Cohen AF. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. 1992;52:402-8  
Verver S (see van Steveninck et al). 1992;52:402-8  
Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. HMG-CoA reductase inhibitors and sleep. 1992;52:110-1 (Letter reply)  
Voorhees JJ (see Watkins et al). 1992;52:265-73  
Voutilainen E (see Karhapää et al). 1992;52:620-6  
Vuorilehto L (see Scheinin et al). 1992;52:537-46

## W

- Wallach-Kapon R (see Alcalay et al). 1992;52:518-27  
Walson PD (see Kelley et al). 1992;52:181-9  
Wang SS (see Lin et al). 1992;52:134-8  
Warren CP (see Sitar et al). 1992;52:297-306  
Wassenaar W (see Hunter et al). 1992;52:60-7  
Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, Fishman K, Guzelian PS, Voorhees JJ. Comparison of urinary 6- $\beta$ -cortisol and the erythromycin breath test as measures of hepatic P450III<sub>A</sub> (CYP3A) activity. 1992;52:265-73

—— (see Turgeon et al). 1992;52:471-8

- Weinberger MM. Drug clearance in patients with cystic fibrosis. 1992;52:106 (Letter)  
Weinberger MS (see Cooper et al). 1992;52:11-23  
Welage L (see Lebsack et al). 1992;52:252-6  
Welker HA (see Schmitt et al). 1992;52:314-23  
Welsh M (see Lindholm et al). 1992;52:359-71  
Wernstedt L (see Hirsch et al). 1992;52:394-401  
Wesnes K (see van Harten et al). 1992;52:427-35  
Whalen JJ (see Abraham et al). 1992;52:205-13  
Whitehead EM, O'Sullivan GM, Lloyd J, Bullingham RES. A new method for rate of analgesic onset: two doses of intravenous morphine compared with placebo. 1992;52:197-204  
Wilkinson GR (see Black et al). 1992;52:659-67  
Williams B (see Leow et al). 1992;52:487-95  
Wing L (see Tonkin and Wing). 1992;52:277-85  
Woittiez AJJ (see Schmitt et al). 1992;52:314-23  
Wolf DL (see Tice et al). 1992;52:496-503  
Wood AJJ (see Zhou et al). 1992;52:120-4  
Woodward WR (see Gancher et al). 1992;52:504-10  
Woosley RL (see Honig et al). 1992;52:231-8  
—— (see Yasuda and Woosley). 1992;52:577-82 (Commentary)  
Wurst W (see Belz et al). 1992;52:68-79

## Y

- Yasuda SU, Woosley RL. The clinical value of FDA class C drugs improved from 1981 to 1988. 1992;52:577-82 (Commentary)

## Z

- Zamani K (see Honig et al). 1992;52:231-8  
Zaninotto M (see Palatini et al). 1992;52:378-83  
Zech K (see Belz et al). 1992;52:68-79  
Zhou HH, Adedoyin A, Wood AJJ. Differing effect of atropine on the heart rate in Chinese and white subjects. 1992;52:120-4  
Zuccaro P (see Rosa et al). 1992;52:324-9

## Subject index

### A

#### ACE inhibitors

Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril (Palatini et al). 1992;52:378-83

#### Acetaminophen

The efficacy of locally applied aspirin and acetaminophen in post-operative pain after third molar surgery (Moore et al). 1992;52:292-6

Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children (Kelley et al). 1992;52:181-9

#### Acetylation

Acetylation polymorphism of caffeine in a Japanese population (Hashiguchi and Ebihara). 1992;52:274-6

#### Acetylcysteine

*N*-Acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses (Iversen). 1992;52:125-33

#### Acetyltransferase

Racial and gender differences in *N*-acetyltransferase, xanthine oxidase, and CYP1A2 activities (Relling et al). 1992;52:643-58

#### Administration, cutaneous

Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption (Benowitz et al). 1992;52:223-30

#### Administration, intranasal

Nasal spray nicotine replacement suppresses cigarette smoking desire and behavior (Perkins et al). 1992;52:627-34

#### Aged

Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma (Sitar et al). 1992;52:297-306

Platelet  $\alpha_2$ -adrenergic receptor responsiveness is increased in elderly men but not in elderly women (Nies et al). 1992;52:605-8

#### Aging

Aging and susceptibility to drug-induced orthostatic hypotension (Tonkin and Wing). 1992;52:277-85

#### Alcohol

Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function (van Harten et al). 1992;52:427-35

#### Alcohol, ethyl

Arteriovenous differences of blood alcohol concentrations after celiac plexus block (Sato et al). 1992;52:249-51

Verapamil inhibits ethanol elimination and prolongs the perception of intoxication (Bauer et al). 1992;52:6-10

#### Alcoholism

Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa (George et al). 1992;52:553-60

#### Alfentanil

The relationship between alfentanil distribution kinetics and cardiac output (Henthorn et al). 1992;52:190-6

#### Alglucerase

Alglucerase (USAN List No. 345). 1992;52:669

#### Alosetron hydrochloride

Alosetron hydrochloride (USAN List No. 341). 1992;52:220

#### Alovudine

Alovudine (USAN List No. 341). 1992;52:222

#### Alpha adrenergic receptors; see Receptors, adrenergic, alpha

#### Alprazolam

Fluoxetine impairs clearance of alprazolam but not of clonazepam (Greenblatt et al). 1992;52:479-86

#### American Society for Clinical Pharmacology and Therapeutics

Clinical pharmacology curriculum review course. 1992;52:668

Future meeting dates and sites of the ASCPT. 1992;52:30, 180

List of contributors. 1992;52:444

July, pp. 1-114; August, pp. 115-222; September, pp. 223-334; October, pp. 335-448; November, pp. 449-576; December, pp. 577-690.

**American Society for Clinical Pharmacology and Therapeutics—cont'd**

- A message from the Finance Committee Chairman. 1992;52:573  
A message from the President—Come to Hawaii March 24-26, 1993. 1992;52:573  
Nominations for awards. 1992;52:330-2

**Amitriptyline**

- Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes (Breyer-Pfaff et al). 1992;52:350-8

**Amlodipine**

- Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II (Donati et al). 1992;52:50-9

**Analgesia**

- A new method for rate of analgesic onset: two doses of intravenous morphine compared with placebo (Whitehead et al). 1992;52:197-204

**Angiotensin II**

- Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II (Donati et al). 1992;52:50-9

**Antihistamines**

- Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans (Billah et al). 1992;52:151-9

**Antihypertensives**

- Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II (Donati et al). 1992;52:50-9  
Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril (Palatini et al). 1992;52:378-83  
Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension (Schmitt et al). 1992;52:314-23  
Plasma concentration-effect relationships for felodipine: a meta analysis (Blychert et al). 1992;52:80-9

**Antineoplastic agents**

- Adaptive control with feedback strategies for suramin dosing (Cooper et al). 1992;52:11-23

**Antiplatelet-activating factor**

- Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans (Billah et al). 1992;52:151-9

**Apomorphine**

- Time course of tolerance to apomorphine in parkinsonism (Gancher et al). 1992;52:504-10

**Arteriovenous changes**

- Arteriovenous differences of blood alcohol concentrations after celiac plexus block (Sato et al). 1992;52:249-51

**Artilede fumarate**

- Artilede fumarate (USAN List No. 341). 1992;52:221

**Aspirin**

- The efficacy of locally applied aspirin and acetaminophen in post-operative pain after third molar surgery (Moore et al). 1992;52:292-6  
Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses (Bergmann et al). 1992;52:413-6

**Asthma**

- Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma (Sitar et al). 1992;52:297-306

**Atropine**

- Differing effect of atropine on the heart rate in Chinese and white subjects (Zhou et al). 1992;52:120-4  
Paradoxical pharmacodynamic effect of atropine on parasympathetic control: a study by spectral analysis of heart rate fluctuations (Alcalay et al). 1992;52:518-27

**Attention deficit disorder with hyperactivity**

- Enantioselective pharmacokinetics and pharmacodynamics of *dl*-threo-methylphenidate in children with attention deficit hyperactivity disorder (Srinivas et al). 1992;52:561-8

**Autonomic nervous system**

- The effects of rilmenidine on tests of autonomic function in humans (McKaigue and Harron). 1992;52:511-7

**B****Bambuterol**

- Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma (Sitar et al). 1992;52:297-306

**Bezafibrate**

- Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia (Karhapää et al). 1992;52:620-6

**Bias**

- Publication bias: its implications for clinical pharmacology (Levy). 1992;52:115-9 (Commentary)

**Bindarit**

- Bindarit (USAN List No. 342). 1992;52:333

**Bioavailability**

- Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction (Hebert et al). 1992;52:453-7  
A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans (Bredberg et al). 1992;52:239-48  
Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability (Lindholm et al). 1992;52:359-71  
Rifabutin absorption in humans: relative bioavailability and food effect (Narang et al). 1992;52:335-41

**Blood flow, regional; see Regional blood flow****Blood platelets**

- Platelet  $\alpha_2$ -adrenergic receptor responsiveness is increased in elderly men but not in elderly women (Nies et al). 1992;52:605-8

**Books received**

- Books received. 1992;52:114, 672

**Breath tests**

- Comparison of urinary 6- $\beta$ -cortisol and the erythromycin breath test as measures of hepatic P450III<sub>A</sub> (CYP3A) activity (Watkins et al). 1992;52:265-73  
Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients (Turgeon et al). 1992;52:471-8  
Increase of cytochrome P450IIA<sub>2</sub> activity by omeprazole: evidence by the <sup>13</sup>C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of *S*-mephenytoin (Rost et al). 1992;52:170-80

**Bronchodilators**

- Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma (Sitar et al). 1992;52:297-306



C

**Caffeine**

- Acetylation polymorphism of caffeine in a Japanese population (Hashiguchi and Ebihara). 1992;52:274-6
- Increase of cytochrome P450IA2 activity by omeprazole: evidence by the <sup>13</sup>C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin (Rost et al). 1992;52:170-80

**Calcium channel blockers**

- Differential effects of two dihydropyridine calcium antagonists in humans (Belz et al). 1992;52:68-79
- Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension (Schmitt et al). 1992;52:314-23

**Cancer; see Neoplasms**

**Carbetocin**

- Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus (Hunter et al). 1992;52:60-7

**Cardiac output**

- The relationship between alfentanil distribution kinetics and cardiac output (Henthorn et al). 1992;52:190-6

**Carsatrin succinate**

- Carsatrin succinate (USAN List No. 344). 1992;52:574

**Cefpirome**

- Single-dose pharmacokinetics of cefpirome in patients with renal impairment (Lameire et al). 1992;52:24-30

**Celiac plexus block**

- Arteriovenous differences of blood alcohol concentrations after celiac plexus block (Sato et al). 1992;52:249-51

**Child**

- Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance (Matsui et al). 1992;52:102-3
- Comparison of intravenous ketorolac with morphine for postoperative pain in children (Maunukela et al). 1992;52:436-43
- Enantioselective pharmacokinetics and pharmacodynamics of *dl*-threo-methylphenidate in children with attention deficit hyperactivity disorder (Srinivas et al). 1992;52:561-8
- Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children (Kelley et al). 1992;52:181-9

**China**

- Differing effect of atropine on the heart rate in Chinese and white subjects (Zhou et al). 1992;52:120-4

**Ciclopilox**

- Ciclopilox (USAN List No. 345). 1992;52:670

**Cigarette smoking; see Smoking**

**Cirrhosis; see Liver cirrhosis**

**Citalopram**

- The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy (Sindrup et al). 1992;52:547-52

**Class C drugs**

- The clinical value of FDA class C drugs approved from 1981 to 1988 (Yasuda and Woosley). 1992;52:577-82 (Commentary)

**Clinafloxacin hydrochloride**

- Clinafloxacin hydrochloride (USAN List No. 343). 1992;52:445

**Clinical trials**

- Failure of controlled clinical trial data to reach the literature (Mindel). 1992;52:4-5 (Commentary)

**Clonazepam**

- Fluoxetine impairs clearance of alprazolam but not of clonazepam (Greenblatt et al). 1992;52:479-86

**Cognition**

- Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function (van Harten et al). 1992;52:427-35

**Commentaries**

- Commentaries. 1992;52:1-5, 115-9, 449-52, 577-82

**Compliance; see Patient compliance**

**Conditioning**

- Classic conditioning and placebo effects in crossover studies (Suchman and Ader). 1992;52:372-7

**Congestive heart failure; see Heart failure, congestive**

**Constipation**

- Treatment of opioid-induced constipation with oral naloxone: a pilot study (Culpepper-Morgan et al). 1992;52:90-5

**Corrections**

- Human *N*-acetylation genotype determination with urinary caffeine metabolites (Kilbane et al) (1990;47:470-7). 1992;52:349
- Influence of time of administration on verapamil pharmacokinetics (Hla et al) (1992;51:366-70). 1992;52:393
- Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study (Weintraub et al) (1992;51:581-646). 1992;52:323

**Cortisol**

- Comparison of urinary 6- $\beta$ -cortisol and the erythromycin breath test as measures of hepatic P450III<sub>A</sub> (CYP3A) activity (Watkins et al). 1992;52:265-73

**Cotinine**

- How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake (Rosa et al). 1992;52:324-9

**Cranial artery**

- N*-Acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses (Iversen). 1992;52:125-33

**Crossover studies**

- Classic conditioning and placebo effects in crossover studies (Suchman and Ader). 1992;52:372-7

**Cyclosporine**

- Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction (Hebert et al). 1992;52:453-7
- Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability (Lindholm et al). 1992;52:359-71
- Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients (Turgeon et al). 1992;52:471-8

**CYP1A2**

- Racial and gender differences in *N*-acetyltransferase, xanthine oxidase, and CYP1A2 activities (Relling et al). 1992;52:643-58

**Cytochrome P450**

- Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease (Black et al). 1992;52:659-67
- Comparison of urinary 6- $\beta$ -cortisol and the erythromycin breath test as measures of hepatic P450III<sub>A</sub> (CYP3A) activity (Watkins et al). 1992;52:265-73
- Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes (Breyer-Pfaff et al). 1992;52:350-8
- Increase of cytochrome P450IA2 activity by omeprazole: evidence by the <sup>13</sup>C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin (Rost et al). 1992;52:170-80
- Racial and gender differences in *N*-acetyltransferase, xanthine oxidase, and CYP1A2 activities (Relling et al). 1992;52:643-58

## D

**Danaparoid sodium**

Danaparoid sodium (USAN List No. 344). 1992;52:575

**Dapsone**

Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease (Black et al). 1992;52:659-67

**Debrisoquin**

Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease (Black et al). 1992;52:659-67

Ethylmorphine *O*-deethylation cosegregates with the debrisoquin genetic metabolic polymorphism (Rane et al). 1992;52:257-64

**Developing countries**

Dose-response variation among different populations (Damansjah and Muchtar). 1992;52:449-52 (Commentary)

**Dexmedetomidine**

Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine (Scheinin et al). 1992;52:537-46

**Dextromethorphan**

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes (Breyer-Pfaff et al). 1992;52:350-8

**Dezinamide**

Dezinamide (USAN List No. 341). 1992;52:222

**Diabetic neuropathy**

The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy (Sindrup et al). 1992;52:547-52

**Diazepam**

Incidence of *S*-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics (Sohn et al). 1992;52:160-9

Influence of lansoprazole treatment on diazepam plasma concentrations (Lefebvre et al). 1992;52:458-63

Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time (Friedman et al). 1992;52:139-50

**Digit Symbol Substitution Test**

Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time (Friedman et al). 1992;52:139-50

**Dihydropyridine**

Differential effects of two dihydropyridine calcium antagonists in humans (Belz et al). 1992;52:68-79

**Dose-response relationship**

Dose-response variation among different populations (Damansjah and Muchtar). 1992;52:449-52 (Commentary)

**Doxacurium**

Population pharmacodynamics of doxacurium (Schmith et al). 1992;52:528-36

**Drug evaluation**

Shortcuts in drug evaluation (Stolley and Lasky). 1992;52:1-3 (Commentary)

## E

**Echocardiography**

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers (de Mey et al). 1992;52:609-19

**Echocardiography**

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers (de Mey et al). 1992;52:609-19

**Elderly; see Aged****Electrocardiography**

Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin (Honig et al). 1992;52:231-8

Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time (Friedman et al). 1992;52:139-50

Prediction of sotalol-induced maximum steady-state QT<sub>c</sub> prolongation from single-dose administration in healthy volunteers (Le Coz et al). 1992;52:417-26

**Endothelins**

Endothelin-1-mediated vasoconstriction: specific blockade by verapamil (Andrews et al). 1992;52:583-9

**Enofelast**

Enofelast (USAN List No. 343). 1992;52:445

**Enoxacin**

Effect of gastric acidity on enoxacin absorption (Lebsack et al). 1992;52:252-6

**Epoetin**

Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies (Abraham et al). 1992;52:205-13

**Ersofermin**

Ersofermin (USAN List No. 345). 1992;52:671

**Erythromycin**

Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin (Honig et al). 1992;52:231-8

Comparison of urinary 6- $\beta$ -cortisol and the erythromycin breath test as measures of hepatic P450III<sub>A</sub> (CYP3A) activity (Watkins et al). 1992;52:265-73

Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients (Turgeon et al). 1992;52:471-8

**Erythropoiesis**

Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies (Abraham et al). 1992;52:205-13

**Ethanol; see Alcohol, ethyl****Ethylmorphine**

Ethylmorphine *O*-deethylation cosegregates with the debrisoquin genetic metabolic polymorphism (Rane et al). 1992;52:257-64

**Eye movements**

Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers (van Steveninck et al). 1992;52:402-8

## F

**FDA classification**

The clinical value of FDA class C drugs approved from 1981 to 1988 (Yasuda and Woosley). 1992;52:577-82 (Commentary)

**Feedback**

Adaptive control with feedback strategies for suramin dosing (Cooper et al). 1992;52:11-23

**Felbamate**

Felbamate (USAN List No. 344). 1992;52:574

**Felodipine**

Plasma concentration-effect relationships for felodipine: a meta analysis (Blychert et al). 1992;52:80-9

**Fever**

Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children (Kelley et al). 1992;52:181-9

**Fluoxetine**

Fluoxetine impairs clearance of alprazolam but not of clonazepam (Greenblatt et al). 1992;52:479-86

### Fluvoxamine

Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function (van Harten et al). 1992;52:427-35

### Foods

Rifabutin absorption in humans: relative bioavailability and food effect (Narang et al). 1992;52:335-41

## G

### Gastric acids

Effect of gastric acidity on enoxacin absorption (Lebsack et al). 1992;52:252-6

### Gastric ulcer

Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison (Cloud et al). 1992;52:307-13

Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses (Bergmann et al). 1992;52:413-6

### Gender factors

Platelet  $\alpha_2$ -adrenergic receptor responsiveness is increased in elderly men but not in elderly women (Nies et al). 1992;52:605-8

Racial and gender differences in *N*-acetyltransferase, xanthine oxidase, and CYP1A2 activities (Relling et al). 1992;52:643-58

### Gleamaserin

Gleamaserin (USAN List No. 341). 1992;52:222

### Glucose

Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia (Karhapää et al). 1992;52:620-6

### Glycerol dinitrate

Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins (Haefeli et al). 1992;52:590-6

### Guest reviewers

Guest reviewers. 1992;52:572

## H

### Headache

*N*-Acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses (Iversen). 1992;52:125-33

Psychoactivity and abuse potential of sumatriptan (Sullivan et al). 1992;52:635-42

### Heart failure, congestive

Clinical pharmacology of nicorandil in patients with congestive heart failure (Tice et al). 1992;52:496-503

### Heart rate

Differing effect of atropine on the heart rate in Chinese and white subjects (Zhou et al). 1992;52:120-4

Paradoxical pharmacodynamic effect of atropine on parasympathetic control: a study by spectral analysis of heart rate fluctuations (Alcalay et al). 1992;52:518-27

### Hemodynamics

Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension (Schmitt et al). 1992;52:314-23

Hemodynamic effects of the use of oral snuff (Hirsch et al). 1992;52:394-401

### Hepatitis

The feasibility of studying drug-induced acute hepatitis with use of Medicaid data (Carson et al). 1992;52:214-9

### Hepatitis B surface antigens

Octreotide decreased liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis (Lin et al). 1992;52:134-8

### Histamines

Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans (Billah et al). 1992;52:151-9

### HIV

Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus (Sahai et al). 1992;52:464-70

### Human immunodeficiency virus; see HIV

### Hydroxylation

Incidence of *S*-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics (Sohn et al). 1992;52:160-9

### Hydroxytryptophan

Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa (George et al). 1992;52:553-60

### Hyperlipidemia

Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia (Karhapää et al). 1992;52:620-6

### Hypertension

Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II (Donati et al). 1992;52:50-9

Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril (Palatini et al). 1992;52:378-83

Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension (Schmitt et al). 1992;52:314-23

Plasma concentration-effect relationships for felodipine: a meta analysis (Blychert et al). 1992;52:80-9

### Hypotension

Aging and susceptibility to drug-induced orthostatic hypotension (Tonkin and Wing). 1992;52:277-85

## I

### Ibuprofen

Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children (Kelley et al). 1992;52:181-9

### Impedance cardiography

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers (de Mey et al). 1992;52:609-19

### Infant

Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants (Pokela et al). 1992;52:342-9

### Infant, newborn

Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants (Pokela et al). 1992;52:342-9

### Infusions, intravenous

Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption (Benowitz et al). 1992;52:223-30

**Injections, intramuscular**

Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine (Scheinin et al). 1992;52:537-46

**Injections, intravenous**

A new method for rate of analgesic onset: two doses of intravenous morphine compared with placebo (Whitehead et al). 1992;52:197-204

Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants (Pokela et al). 1992;52:342-9

**Insulin**

Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia (Karhapää et al). 1992;52:620-6

**Intoxication**

Arteriovenous differences of blood alcohol concentrations after celiac plexus block (Sato et al). 1992;52:249-51

Verapamil inhibits ethanol elimination and prolongs the perception of intoxication (Bauer et al). 1992;52:6-10

**Intramuscular injections; see Injections, intramuscular****Intravenous infusions; see Infusions, intravenous****Intravenous injections; see Injections, intravenous****Isoproterenol**

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers (de Mey et al). 1992;52:609-19

**Isotopes**

A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans (Bredberg et al). 1992;52:239-48

**J****Japan**

Acetylation polymorphism of caffeine in a Japanese population (Hashiguchi and Ebihara). 1992;52:274-6

**K****Ketorolac**

Comparison of intravenous ketorolac with morphine for postoperative pain in children (Maunukela et al). 1992;52:436-43

**Kidney failure**

Single-dose pharmacokinetics of cefpirome in patients with renal impairment (Lameire et al). 1992;52:24-30

**Kidney transplantation**

Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients (Turgeon et al). 1992;52:471-8

Pharmacokinetics and biochemical efficacy of piroxicam, a thromboxane synthase inhibitor, in renal allograft recipients (Chouinard et al). 1992;52:597-604

**Korea**

Incidence of *S*-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics (Sohn et al). 1992;52:160-9

**L****L-654,066**

Pharmacodynamics and tolerability of L-654,066, a steroid 5 $\alpha$ -reductase inhibitor in men (Depré et al). 1992;52:409-12

**Lamivudine**

Lamivudine (USAN List No. 341). 1992;52:220

**Lansoprazole**

Influence of lansoprazole treatment on diazepam plasma concentrations (Lefebvre et al). 1992;52:458-63

Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses (Bergmann et al). 1992;52:413-6

**Lenograstim**

Lenograstim (USAN List No. 340). 1992;52:113

**Letters**

Drug clearance in patients with cystic fibrosis (Weinberger) (Letter); (Unadkat et al) (Reply). 1992;52:106-7

HMG-CoA reductase inhibitors and sleep (Spielberg and Tobert) (Letter); (Vgontzas et al) (Reply). 1992;52:109-11

Pharmacokinetics of fosinopril (Shahinfar and Shaw) (Letter); (Hui) (Reply). 1992;52:569

Statistics and clinical trials (Rodda et al) (Letter); (Sheiner) (Reply). 1992;52:

Theophylline metabolism affected by mexiletine (Rost et al) (Letter); (Hurwitz et al) (Reply). 1992;52:107-9

Vancomycin levels and acute renal failure (Brackett) (Letter); (Mueller et al) (Reply). 1992;52:570-1

**Levodopa**

Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa (George et al). 1992;52:553-60

**Linopirdine**

Linopirdine (USAN List No. 343). 1992;52:445

**Literature**

Failure of controlled clinical trial data to reach the literature (Mindel). 1992;52:4-5 (Commentary)

Publication bias: its implications for clinical pharmacology (Levy). 1992;52:115-9 (Commentary)

**Liver**

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction (Hebert et al). 1992;52:453-7

Octreotide decreased liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis (Lin et al). 1992;52:134-8

**Liver cirrhosis**

Octreotide decreased liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis (Lin et al). 1992;52:134-8

**Losoxantrone hydrochloride**

Losoxantrone hydrochloride (USAN List No. 341). 1992;52:222

**M****Marijuana**

Characterization of the absorption phase of marijuana smoking (Huestis et al). 1992;52:31-41

**Mechanocardiography**

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers (de Mey et al). 1992;52:609-19

**Medicaid**

The feasibility of studying drug-induced acute hepatitis with use of Medicaid data (Carson et al). 1992;52:214-9

**Medication Event Monitoring System**

Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance (Matsui et al). 1992;52:102-3

**Meperidine**

Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants (Pokela et al). 1992;52:342-9

# **Mephenytoin**

- Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease (Black et al). 1992;52:659-67
- Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes (Breyer-Pfaff et al). 1992; 52:350-8
- Incidence of *S*-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics (Sohn et al). 1992;52:160-9
- Increase of cytochrome P450IA2 activity by omeprazole: evidence by the <sup>13</sup>C-[*N*-3-methyl]-caffeine breath test in poor and extensive metabolizers of *S*-mephenytoin (Rost et al). 1992;52: 170-80

# **Meropenem**

- Meropenem (USAN List No. 345). 1992;52:670

# **Methylphenidate**

- Enantioselective pharmacokinetics and pharmacodynamics of *dl*-*threo*-methylphenidate in children with attention deficit hyperactivity disorder (Srinivas et al). 1992;52:561-8

# **Moclobemide**

- Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers (Simpson and Gratz). 1992;52:286-91

# **Molgramostim**

- Molgramostim (USAN List No. 340). 1992;52:112

# **Monoamine oxidase inhibitors**

- Pharmacokinetic and pharmacodynamic interaction between tolatoxone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects (Provost et al). 1992;52: 384-93

# **Morphine**

- Comparison of intravenous ketorolac with morphine for postoperative pain in children (Maunuksela et al). 1992;52:436-43
- A new method for rate of analgesic onset: two doses of intravenous morphine compared with placebo (Whitehead et al). 1992;52: 197-204

## **N**

# **Naloxone**

- Treatment of opioid-induced constipation with oral naloxone: a pilot study (Culpepper-Morgan et al). 1992;52:90-5

# **Naproxen**

- Evaluation of the *in vivo* effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus (Sahai et al). 1992;52:464-70

# **Nasal spray; see Administration, intranasal**

# **Nausea**

- Ondansetron is effective in decreasing postoperative nausea and vomiting (Dershwitz et al). 1992;52:96-101

# **Neonate; see Infant, newborn**

# **Neoplasms**

- Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer (Leow et al). 1992;52:487-95

# **Nicorandil**

- Clinical pharmacology of nicorandil in patients with congestive heart failure (Tice et al). 1992;52:496-503

# **Nicotine**

- How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake (Rosa et al). 1992;52:324-9
- Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption (Benowitz et al). 1992;52:223-30

- Nasal spray nicotine replacement suppresses cigarette smoking desire and behavior (Perkins et al). 1992;52:627-34

# **Nifedipine**

- Differential effects of two dihydropyridine calcium antagonists in humans (Belz et al). 1992;52:68-79

# **Niguldipine**

- Differential effects of two dihydropyridine calcium antagonists in humans (Belz et al). 1992;52:68-79

# **Nitroglycerin**

- N*-Acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses (Iversen). 1992;52:125-33
- Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins (Haefeli et al). 1992;52: 590-6

# **Nizatidine**

- Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison (Cloud et al). 1992;52:307-13

# **Norepinephrine**

- Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II (Donati et al). 1992;52:50-9

## **O**

# **Ocreotide**

- Ocreotide decreased liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis (Lin et al). 1992;52: 134-8

# **Omeprazole**

- Increase of cytochrome P450IA2 activity by omeprazole: evidence by the <sup>13</sup>C-[*N*-3-methyl]-caffeine breath test in poor and extensive metabolizers of *S*-mephenytoin (Rost et al). 1992;52: 170-80

# **Ondansetron**

- Ondansetron is effective in decreasing postoperative nausea and vomiting (Dershwitz et al). 1992;52:96-101

# **Opioids**

- Treatment of opioid-induced constipation with oral naloxone: a pilot study (Culpepper-Morgan et al). 1992;52:90-5

# **Oral surgery**

- The efficacy of locally applied aspirin and acetaminophen in postoperative pain after third molar surgery (Moore et al). 1992; 52:292-6

# **Orthostatic hypotension; see Hypotension**

# **Oxycodone**

- Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer (Leow et al). 1992;52:487-95

# **Oxytocin**

- Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus (Hunter et al). 1992;52:60-7

## **P**

# **Pain, postoperative**

- Comparison of intravenous ketorolac with morphine for postoperative pain in children (Maunuksela et al). 1992;52:436-43
- The efficacy of locally applied aspirin and acetaminophen in postoperative pain after third molar surgery (Moore et al). 1992; 52:292-6

# **Parasympathetic nervous system**

- Paradoxical pharmacodynamic effect of atropine on parasympathetic control: a study by spectral analysis of heart rate fluctuations (Alcalay et al). 1992;52:518-27



**Parkinson's disease**

Time course of tolerance to apomorphine in parkinsonism (Ganther et al). 1992;52:504-10

**Patient compliance**

Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance (Matsui et al). 1992;52:102-3

**Phenelzine**

Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers (Simpson and Gratz). 1992;52:286-91

**Phlebotomy**

Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies (Abraham et al). 1992;52:205-13

**Pirmagrel**

Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients (Chouinard et al). 1992;52:597-604

**Placebos**

Classic conditioning and placebo effects in crossover studies (Suchman and Ader). 1992;52:372-7

A new method for rate of analgesic onset: two doses of intravenous morphine compared with placebo (Whitehead et al). 1992;52:197-204

Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison (Cloud et al). 1992;52:307-13

**Platelet-activating factor**

Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans (Billah et al). 1992;52:151-9

**Platelets; see Blood platelets****Polymorphism**

Acetylation polymorphism of caffeine in a Japanese population (Hashiguchi and Ebihara). 1992;52:274-6

Ethylmorphine *O*-deethylation cosegregates with the debrisoquin genetic metabolic polymorphism (Rane et al). 1992;52:257-64

**Population**

Population pharmacodynamics of doxacurium (Schmith et al). 1992;52:528-36

**Postoperative complications**

Ondansetron is effective in decreasing postoperative nausea and vomiting (Derishwitz et al). 1992;52:96-101

**Postoperative pain; see Pain, postoperative****Postpartum period**

Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus (Hunter et al). 1992;52:60-7

**Protein C**

The effect of the plasma levels of proteins C and S on the prediction of warfarin maintenance dose requirements (Lubetsky et al). 1992;52:42-9

**Protein S**

The effect of the plasma levels of proteins C and S on the prediction of warfarin maintenance dose requirements (Lubetsky et al). 1992;52:42-9

**Publications**

Publication bias: its implications for clinical pharmacology (Levy). 1992;52:115-9 (Commentary)

**Q****QT interval; see Electrocardiography****Quinapril**

Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril (Palatini et al). 1992;52:378-83

**R****Racial factors**

Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability (Lindholm et al). 1992;52:359-71

Differing effect of atropine on the heart rate in Chinese and white subjects (Zhou et al). 1992;52:120-4

Racial and gender differences in *N*-acetyltransferase, xanthine oxidase, and CYP1A2 activities (Relling et al). 1992;52:643-58

**Ramoplanin**

Ramoplanin (USAN List No. 343). 1992;52:446-8

**Receptors, adrenergic, alpha**

Platelet  $\alpha_2$ -adrenergic receptor responsiveness is increased in elderly men but not in elderly women (Nies et al). 1992;52:605-8

**Regional blood flow**

Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption (Benowitz et al). 1992;52:223-30

**Remifentanyl hydrochloride**

Remifentanyl hydrochloride (USAN List No. 341). 1992;52:220

**Renal impairment; see Kidney failure****Renal transplantation; see Kidney transplantation****Reviewers**

List of reviewers. 1992;52:572

**Rifabutin**

Rifabutin absorption in humans: relative bioavailability and food effect (Narang et al). 1992;52:335-41

**Rifamexil**

Rifamexil (USAN List No. 341). 1992;52:221

**Rifampin**

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction (Hebert et al). 1992;52:453-7

**Rifaximin**

Rifaximin (USAN List No. 342). 1992;52:334

**Rilmenidine**

The effects of rilmenidine on tests of autonomic function in humans (McKague and Harron). 1992;52:111-7

**Ro 40-5967**

Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension (Schmitt et al). 1992;52:314-23

**S****Saccades**

Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers (van Steveninck et al). 1992;52:402-8

**Sargramostim**

Sargramostim (USAN List No. 340). 1992;52:112

**Sch 37370**

Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans (Billah et al). 1992;52:151-9

**Selegiline hydrochloride**

Selegiline hydrochloride (USAN List No. 342). 1992;52:333

**Serotonin inhibitors**

The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy (Sindrup et al). 1992;52:547-52

**Sertindole**

Sertindole (USAN List No. 342). 1992;52:333

# Smoking

- Characterization of the absorption phase of marijuana smoking (Huestis et al). 1992;52:31-41
- How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake (Rosa et al). 1992;52:324-9
- Nasal spray nicotine replacement suppresses cigarette smoking desire and behavior (Perkins et al). 1992;52:627-34

# Snuff

- Hemodynamic effects of the use of oral snuff (Hirsch et al). 1992;52:394-401

# Sotalol

- Prediction of sotalol-induced maximum steady-state QT<sub>c</sub> prolongation from single-dose administration in healthy volunteers (Le Coz et al). 1992;52:417-26

# Steroids

- Pharmacodynamics and tolerability of L-654,066, a steroid 5 $\alpha$ -reductase inhibitor in men (Depré et al). 1992;52:409-12

# Substance abuse

- Psychoactivity and abuse potential of sumatriptan (Sullivan et al). 1992;52:635-42

# Sulopenem

- Sulopenem (USAN List No. 345). 1992;52:670

# Sumatriptan

- Psychoactivity and abuse potential of sumatriptan (Sullivan et al). 1992;52:635-42

# Suramin

- Adaptive control with feedback strategies for suramin dosing (Cooper et al). 1992;52:11-23

## T

# Tacrolimus

- Tacrolimus (USAN List No. 344). 1992;52:576

# Teloxantrone hydrochloride

- Teloxantrone hydrochloride (USAN List No. 342). 1992;52:334

# Temazepam

- Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers (van Steveninck et al). 1992;52:402-8

# Terbutaline

- A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans (Bredberg et al). 1992;52:239-48
- Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma (Sitar et al). 1992;52:297-306

# Terfenadine

- Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin (Honig et al). 1992;52:231-8

# Tetrahydrocannabinol

- Characterization of the absorption phase of marijuana smoking (Huestis et al). 1992;52:31-41

# Tetrazolast meglumine

- Tetrazolast meglumine (USAN List No. 342). 1992;52:334

# Third molar surgery; see Oral surgery

# Thromboxanes

- Pharmacokinetics and biochemical efficacy of pimgagrel, a thromboxane synthase inhibitor, in renal allograft recipients (Chouinard et al). 1992;52:597-604

# Tobacco, smokeless

- Hemodynamic effects of the use of oral snuff (Hirsch et al). 1992;52:394-401

# Toloxatone

- Pharmacokinetic and pharmacodynamic interaction between tolaxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects (Provost et al). 1992;52:384-93

# Transdermal administration; see Administration, cutaneous Trefentanil hydrochloride

- Trefentanil hydrochloride (USAN List No. 341). 1992;52:221

# Tyramine

- Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers (Simpson and Gratz). 1992;52:286-91
- Pharmacokinetic and pharmacodynamic interaction between tolaxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects (Provost et al). 1992;52:384-93

## U

# Ulcers

- Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison (Cloud et al). 1992;52:307-13
- Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses (Bergmann et al). 1992;52:413-6

# United States Adopted Names Council

- USAN Council. 1992;52:112-3, 220-2, 333-4, 445-8, 574-6, 669-71

# Uremia

- Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability (Lindholm et al). 1992;52:359-71

# Urine

- Comparison of urinary 6- $\beta$ -cortisol and the erythromycin breath test as measures of hepatic P450III<sub>A</sub> (CYP3A) activity (Watkins et al). 1992;52:265-73

# Uterus

- Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus (Hunter et al). 1992;52:60-7

## V

# Vasoconstriction

- Endothelin-I-mediated vasoconstriction: specific blockade by verapamil (Andrawis et al). 1992;52:583-9

# Vasodilation

- Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins (Haefeli et al). 1992;52:590-6

# Verapamil

- Endothelin-I-mediated vasoconstriction: specific blockade by verapamil (Andrawis et al). 1992;52:583-9
- Verapamil inhibits ethanol elimination and prolongs the perception of intoxication (Bauer et al). 1992;52:6-10

# Vinyl chloride

- Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease (Black et al). 1992;52:659-67

# Vomiting

- Ondansetron is effective in decreasing postoperative nausea and vomiting (Dershwitz et al). 1992;52:96-101

## W

# Warfarin

- The effect of the plasma levels of proteins C and S on the prediction of warfarin maintenance dose requirements (Lubetsky et al). 1992;52:42-9

X

**Xamoterol fumarate**

Xamoterol fumarate (USAN List No. 345). 1992;52:669

**Xanthine oxidase**

Racial and gender differences in *N*-acetyltransferase, xanthine oxidase, and CYP1A2 activities (Relling et al). 1992;52:643-58

Z

**Zidovudine**

Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus (Sahai et al). 1992;52:464-70

